Dr Scott Tagawa speaks to ecancer at ESMO 2019 in Barcelona about the phase II TROPHY-U-01 study evaluating the use of sacituzumab govitecan in patients with metastatic urothelial cancer (mUC) after failure of platinum-based regimens or immunotherapy.

He explains that the main cohort contained 100 evaluable patients with mUC and progression of disease despite both platinum-based chemotherapy and checkpoint inhibitors.

Dr Tagawa reports that the response rate overall was 29% which was a marked improvement over single agent chemotherapy.